
Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022
Description
Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022
DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Wet Age-Related Macular Degeneration (Wet-AMD): Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type. The wet/neovascular type affects approximately 10–15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease. It causes 90% of severe vision loss in people with AMD. Everyone who gets wet AMD had dry AMD at one point. Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision. The most common symptoms typical of the onset of exudative AMD are central visual blurring and distortion. Most patients complain that straight lines appear crooked or wavy. Although only 15% of patients with AMD have the wet form, 80–90% of the severe vision loss caused by AMD results from wet AMD. Dilated funduscopic findings are diagnostic; color photographs, fluorescein angiography, and optical coherence tomography assist in confirming the diagnosis and in directing Wet AMD treatment.
""Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet-AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs
Further product details are provided in the report……..
Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.
Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Wet Age-Related Macular Degeneration (Wet-AMD): Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type. The wet/neovascular type affects approximately 10–15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease. It causes 90% of severe vision loss in people with AMD. Everyone who gets wet AMD had dry AMD at one point. Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision. The most common symptoms typical of the onset of exudative AMD are central visual blurring and distortion. Most patients complain that straight lines appear crooked or wavy. Although only 15% of patients with AMD have the wet form, 80–90% of the severe vision loss caused by AMD results from wet AMD. Dilated funduscopic findings are diagnostic; color photographs, fluorescein angiography, and optical coherence tomography assist in confirming the diagnosis and in directing Wet AMD treatment.
""Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet-AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Wet Age-Related Macular Degeneration (Wet-AMD).
- In the coming years, the Wet Age-Related Macular Degeneration (Wet-AMD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Wet Age-Related Macular Degeneration (Wet-AMD) treatment market. Several potential therapies for Wet Age-Related Macular Degeneration (Wet-AMD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Wet Age-Related Macular Degeneration (Wet-AMD) market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs
- LY09004: Luye Pharma
- KSI-301: Kodiak Sciences
- GEM-103: Gemini Therapeutics
- Zimura: Iveric Bio
- RC 28 E: RemeGen
- BI 836880: Boehringer Ingelheim
- AAVCAGsCD59: Janssen Research and Development
Further product details are provided in the report……..
Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Wet Age-Related Macular Degeneration (Wet-AMD)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.
Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights
- Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
- How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Opthea Limited
- Outlook Therapeutics
- Kodiak Sciences
- Regenxbio
- Dobecure
- Gemini Therapeutics
- Huabo Biopharm
- Isarna Therapeutics
- IVERIC bio (formerly Ophthotech Corporation)
- Tasly Pharmaceutical Group
- Ribomic
- Innovent Biologics
- GrayBug Vision
- Curacle
- Quark Pharmaceuticals
- Bio-Thera Solutions
- AngioLab Inc
- Alkahest
- Tyrogenex
- Iconic Therapeutics
- AiViva BioPharma
- Boehringer Ingelheim
- RemeGen
- PanOptica
- Clearside Biomedical
- Feramda
- AsclepiX Therapeutics
- Unity Biotechnology
- Kyowa Kirin
- Ocular Therapeutix
- Janssen Research & Development
- EyePoint Pharmaceuticals
- Shanghai Biomabs Pharmaceutical
- Aerie Pharmaceuticals
- Ashvattha Therapeutics
- Roche
- Roche
- Noveome
- Sunshine Guojian Pharmaceutical (Shanghai)
- Adverum Biotechnologies
- Zhaoke Ophthalmology
- 4D Molecular Therapeutics
- Abpro Corporation
- Novelty Nobility
- Kala Pharmaceuticals
- Kala Pharmaceuticals
- Surrozen
- Samjin Pharm
- OPT-302
- ONS-5010
- KSI-301
- RGX-314
- Etamsylate
- GEM-103
- HB002.1M
- ISTH0036
- Zimura
- Sanhuangjingshimingwan
- RBM-007
- IBI302
- GB-102
- CU03
- PF-04523655
- BAT5906
- ALS-L1023
- AKST4290
- Vorolanib (X-82)
- ICON-1
- AIV007
- BI 836880
- RC 28 E
- PAN 90806
- CLS-AX
- AS101
- AXT107
- UBX1325
- KHK4951
- OTX-TKI
- AAVCAGsCD59
- EYP-1901
- CMAB818
- AR-13503
- D-4517
- RG6120
- RG7921
- ST266
- 601A
- ADVM-022
- TAB014
- 4D-150
- ABP-201
- NN2101
- Research Programme: Tyrosine Kinase Inhibitor
- Research Programme: Selective Glucocorticoid Receptor Modulator (SEGRM)
- Research Programs: wAMD
- SJP1803/1804
Table of Contents
220 Pages
- Introduction
- Executive Summary
- Wet Age-Related Macular Degeneration (Wet-AMD): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Wet Age-Related Macular Degeneration (Wet-AMD) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- LY09004: Luye Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- GEM-103: Gemini Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BI 836880: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- EYS609: Eyevensys
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
- Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
- Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
- Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
- Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.